Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Peking University School of Oncology, Beijing, People's Republic of China.
Department of Pathology, Beijing Cancer Hospital, Peking University School of Oncology, Beijing, People's Republic of China.
J Surg Res. 2014 May 15;188(2):442-50. doi: 10.1016/j.jss.2014.01.017. Epub 2014 Jan 17.
BACKGROUND & AIM: Esophageal squamous cell carcinoma (ESCC), a common disease in China, is mainly treated surgically. We established a prospective database of patients with esophageal cancer between January 2000 and December 2010, including 486 subjects with ESCC who underwent surgical treatment. In this study, we explored the prognostic significance of the expressions of HOXC6 and HOXC8, responsible for embryonic development, by studying the specimens collected from clinical subjects during strict follow-up periods.
MATERIALS & METHODS: Immunohistochemistry was used to detect the expressions of HOXC6 and HOXC8 in 274 ESCC subjects including 138 ESCC subjects treated with surgery alone and 136 ESCC subjects treated with neoadjuvant chemotherapy. Survival analysis was performed from the day of surgery to August 2013.
The 5-y survival rate of the 274 ESCC subjects was 44.2%, with a median survival time of 44.12 mo. For the 274 ESCC subjects involved in the investigation of HOXC6 and HOXC8 expressions, the median survival time of subjects with high-level expressions of HOXC6 and HOXC8 was shorter than that for subjects with low-level expressions (P = 0.001, P < 0.001, respectively). Similar results were obtained from the analysis of the prognostic value of HOXC6 and HOXC8 in the group treated with surgery alone and the group treated with neoadjuvant chemotherapy. Multivariate analysis demonstrated that HOXC6 and HOXC8 expressions were independent prognostic factors in patients with ESCC.
The HOXC6 and HOXC8 genes can be used as prognostic markers in patients with ESCC, but prospective studies are still needed to confirm.
食管鳞状细胞癌（ESCC）是中国的一种常见疾病，主要通过手术治疗。我们建立了一个 2000 年 1 月至 2010 年 12 月期间食管癌患者的前瞻性数据库，其中包括 486 例接受手术治疗的 ESCC 患者。在这项研究中，我们通过对临床患者在严格随访期间采集的标本进行研究，探讨了负责胚胎发育的 HOXC6 和 HOXC8 表达的预后意义。
免疫组织化学法检测了 274 例 ESCC 患者（其中 138 例单独接受手术治疗，136 例接受新辅助化疗）中 HOXC6 和 HOXC8 的表达。生存分析从手术日开始至 2013 年 8 月。
274 例 ESCC 患者的 5 年生存率为 44.2%，中位生存时间为 44.12 个月。在涉及 HOXC6 和 HOXC8 表达的 274 例 ESCC 患者的调查中，高水平表达 HOXC6 和 HOXC8 的患者中位生存时间短于低水平表达 HOXC6 和 HOXC8 的患者（P=0.001，P<0.001）。在单独手术治疗组和新辅助化疗组中，HOXC6 和 HOXC8 的预后价值分析也得到了类似的结果。多变量分析表明，HOXC6 和 HOXC8 的表达是 ESCC 患者的独立预后因素。
HOXC6 和 HOXC8 基因可作为 ESCC 患者的预后标志物，但仍需要前瞻性研究来证实。
